





The endocannabinoid system represents a potential therapeutic target in sepsis due to the presence of cannabinoid 
receptors (CB2) on immune cells. In this review we discuss how various targets within the endocannabinoid system can be 
manipulated to treat the immune consequences of sepsis. One of the targets outlined are the endocannabinoid receptors 
and modulation of their activity through pharmacological agonists and antagonists. Another therapeutic target covered in 
this review is the modulation of the endocannabinoid degradative enzyme’s activity. Modulation of degradative enzyme 
activity can change the levels of endogenous cannabinoids thereby altering immune activity. Overall, activation of the CB2 
receptors causes immunosuppression and can be beneficial during the hyperactivated immune state of sepsis, while 
suppression of the CB2 receptors may be beneficial during a hypoimmune septic state. 
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Introduction
Sepsis is a complex immune disorder 
that can affect the function of almost 
all organ systems in the body. This dis-
order is characterised by a malfunctio-
ning immune response to an infection 
that involves both pro-inflammatory and 
immunosuppressive mediators. This 
leads to severe damage and failure of 
vital organs, resulting in patient death 
(figures 1,2). Sepsis, septic shock, 
and systemic inflammatory response 
syndrome are the leading causes of 
mortality in surgical intensive care unit 
patients internationally. (1) Within the 
United States alone, the incidence of 
sepsis is around 750,000 annually, (2) 
resulting in more than 200,000 deaths. 
(3) 
Older individuals with fragile immune 
systems are at a higher risk of deve-
loping sepsis after invasive surgical 
procedures. Concurrently, the propor-
tion of our ageing population has been 
increasing steadily over the years with 
8% of the population being over 60 
years old in 1950, 11% in 2009, and pre-
dicted to be 22% in 2050. (4) As a result, 
the incidence of sepsis in North Ameri-
ca is projected to rise along with the risk 
of patient mortality. (2) Unfortunately, 
current management of sepsis is limi-
ted to supportive care, and therapeutic 
intervention is mainly hindered by the 
complex pathophysiology and hetero-
geneous immuno-inflammatory nature 
of the disease. (5) Although supportive 
care is beneficial to septic patients, 
there are no specific therapeutic opti-
ons available that target the immune 
system to eliminate septic related mor-
tality. All of these facets have resulted 
in a significant cost to the heath care 
system. (2) 
The current lack of viable therapeutic 
treatment options for sepsis unders-
cores our insufficient understanding of 
this complex disease. The endocanna-
binoid system, a key regulator of essen-
tial physiological functions including 
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the immune system, has recently emer-
ged as a potential therapeutic target 
for sepsis treatment. The endocanna-
binoid system acquires its name from 
the plant Cannabis Sativa, which has 
been used medically to treat a variety 
of ailments, as well as recreationally 
for centuries. Cannabis Sativa contains 
more than 60 active phytocannabino-
ids with the primary phytocannabino-
id 9-tetrahydrocannabinol (THC), (6) 
activating both endogenous endoca-
nnabinoid receptors. (7) 
The endocannabinoid 
system and sepsis 
The endogenous endocannabinoid 
signalling system can be thought of as 
consisting of three main elements that 
mediate its signalling. The first element 
consists of the endocannabinoids or 
bioactive lipid signalling elements. The 
second element is the endocannabinoid 
receptors that bind endocannabinoids. 
Finally, the third element encompasses 
proteins and transporters that mediate 
biosynthesis, transport and degradati-
on of endocannabinoids. (8-11) 
To-date, two endocannabinoid recep-
tors have been identified: cannabinoid 
type 1 (CB1) and cannabinoid type 2 
(CB2) receptors. These receptors are 
members of the Class A Rhodopsin-like 
family of G-protein coupled receptors 
and, therefore, contain seven trans-
membrane domains. Both CB1 and 
CB2, preferentially couple to hetero-
trimeric Gi/o proteins and adenyl 
cyclases, but may also couple to other 
classes of G proteins. (8,9). CB1 recep-
tors were the first cannabinoid recep-
tor to be molecularly cloned. (12) CB1 
receptors are expressed ubiquitously in 
the body, but are most abundant in the 
central nervous system (CNS), where 
they modulate neurotransmitter release. 
(13) In keeping with this, the behaviour-
al effects of cannabinoid ligands are 
associated with the CB1 receptor in the 
CNS. CB2 receptors were discovered 
shortly after the identification of CB1 
receptors, (14) and their expression is 
largely restricted to immune cells such 
as lymphocytes, macrophages, and 
neutrophils. (15) The expression of CB2 
receptors in immune cells in humans is 
as follows; B cells > Natural Killer Cell 
> Monocytes > Polymorphonuclear 
Neutrophils > CD8 Leukocytes > CD4 
Leukocytes. (16) 
Cells involved in the inflammatory 
response can be broadly distinguished 
into two categories: cells present in tis-
sues, and cells that travel in the blood. 
The cells present in the tissues com-
prise of mast cells, endothelial cells and 
tissue macrophages, while the inflam-
matory cells within the blood stream are 
platelets and leukocytes. Leukocytes 
are further subdivided into polymorpho-
nuclear (multi-lobed nuclei) cells and 
mononuclear cells. The polymorpho-
nuclear cells are subdivided into neutro-
phils, basophils, and eosinophils, while 
the mononuclear cells are divided into 
monocytes and lymphocytes. (17) The 
inflammatory cells present in the tissue 
are activated and secrete inflammatory 
mediators when physically damaged 
or chemically stimulated, prompting 
localization of leukocytes to the site of 
damage. Cells of the immune system 
release cytokines that are protein medi-
ators to either increase or decrease the 
inflammatory response. The cytokine 
sub-classification includes interleukins 
(ILs), chemokines, interferons, colony 
stimulating factors, tumour necrosis 
factors (TNFs), and growth factors. (17) 
TNF- and IL-1 are the main pro-inflam-
matory cytokines associated with the 
LPS induced hyper-immune response 
of sepsis, while IL-10 is associated with 
the subsequent immune suppression 
of sepsis immunopathology. (18)
Since the discovery of the cannabinoid 
receptors, extensive research has been 
focused on elucidating their functions; 
(19) we now know that the endocanna-
binoid system is involved in an array of 
diverse functions like immune modula-
tion, cancer, pain processing, anxiety, 
depression, and neuroprotection. (20) 
This diverse influence of the endocan-
nabinoid system has made it an attract-
ive potential drug target for the treat-
ment of a wide array of human disease. 
Multiple pharmacological approaches 
have also been devised to manipulate 
the endocannabinoid system ranging 
from development of synthetic canna-
binoid receptor ligands, to compounds 
that alter the biosynthesis or degrada-
tion of endogenous endocannabinoid 
ligands. (21,22) Due to the predomin-
ance of CB2 receptor expression on 
immune cells, it is likely that they play 
a role in the function of the immune 
system as well as the inflammatory 
response. (23) Therefore modulation 
of these receptors and their ligands 
for therapeutic benefit will be the main 
focus of this review.
Two endogenous endocannabinoids 
have been most extensively studied. 
(24) They are: arachidonoylethanol-
amide (AEA; previously known as anan-
damide), (25) and 2-arachidonoylgly-
cerol (2-AG) (figure 3). (26) Both AEA 
and 2-AG have the ability to activate 
both CB1 and CB2 receptors. AEA and 
2-AG are released locally and have a 
short duration of action; the concen-
trations of these endocannabinoids 
are tightly regulated to avoid exces-
sive stimulation. (10,22) Extracellular 
levels of these two endocannabinoids 
are strictly regulated by the system to 
avoid excess stimulation. The endocan-
nabinoids are rapidly eliminated from 
the extracellular environment through 
cellular reuptake followed by enzyme 
hydrolysis. (10) Two main enzymes are 
responsible for the cytosolic degrada-
tion of the endocannabinoids. Fatty 
acid amide hydrolase (FAAH) is a mem-
brane bound serine hydrolase enzyme 
that is responsible for the hydrolysis 
of AEA as well as a large number of 
endogenous fatty acid amides (figure 
3). (27,28) Monoacylglycerol lipase 
(MAGL) is the primary enzyme respon-
sible for the degradation of 2-AG (fig-
ure 3), (28) however FAAH and a few 
other enzymes also have the ability to 
degrade 2-AG. 
Therapeutic Targets
Effective treatment of sepsis requires the 
proper identification and understanding 
of the patient’s septic state. Current 
understanding now indicates that sep-
sis immunopathogenesis starts with 
an early hyper-inflammatory response 
followed by a later anti-inflammatory 
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response (figure 1). (28,29) Due to this 
biphasic pathology of sepsis, immuno-
suppression through the endocan-
nabinoid system may not always be 
a beneficial therapy. The early hyper-
inflammatory response is characterised 
by an uncontrolled over activation of 
the innate immune response to patho-
gens. During this phase, an excessive 
amount of pro-inflammatory mediators 
are released from immune cells to 
mobilize a defensive response to the 
pathogens. Unfortunately, this exag-
gerated response causes damage to 
the host’s tissue, leading to hypoper-
fusion and eventual organ failure. (28) 
During this phase of sepsis, a reduc-
tion in the release of pro-inflammatory 
cytokines and mediators will be helpful 
to minimize tissue damage. Modula-
tion of the endocannabinoid system, 
particularly CB2, (23) to dampen down 
the inflammatory response during this 
phase of sepsis may be a beneficial 
therapy. Alternatively, patients in later 
stages of sepsis have a suppressed 
immune system, a state initiated by 
their own immune system as a mechan-
ism to counteract the preceding hyper-
immune response. Unfortunately, tissue 
damage and organ failure can continue 
to occur in this phase from the invading 
pathogens left in the system. As a result 
during this phase, modulation of the 
endocannabinoid system to upregulate 
the inflammatory response may help to 




Modulation of the endocannabinoid 
system at the signalling elements, 
receptors or degradative enzymes, 
may provide a potential therapeutic 
benefit during inflammation and sepsis. 
One viable option is to directly target 
cannabinoid receptors using receptor 
selective drugs, where modulation of 
specific receptors can result in thera-
peutic benefit. (30) Previous studies 
have indicated that activation of pre-
synaptic CB1 receptors on autonomic 
nerves and vascular walls contribute to 
the hypotension associated with septic 
shock. (31) This result is not conclusive 
however because when CB1 knock-
out mice were subject to acute endo-
toxemia, acute hypotension was still 
observed. (32) Studies in our own lab 
have found that inhibition of the CB1 
receptor, using the antagonist AM281, 
protected microcirculation of the gut 
and iris during acute endotoxemia. 
(33,34)    
Manipulation of CB2 receptors may 
have good utility in sepsis treatment 
given the localized expression of these 
receptors to macrophages, neutro-
phils and lymphocytes. Activation of 
CB2 receptors is generally associated 
with an antinflammatory effect, with a 
resultant decrease in pro-inflammatory 
cytokines and a reduction in macro-
phage and neutrophil recruitment. (35) 
However, research on the modulation 
of these receptors has also provided 
some contradictory results. (36,37)
A study by Tschöp et al. modulated 
the CB2 receptor in a systemic septic 
model induced through cecal ligation 
Figure 1.  Immune response in sepsis and potential therapeutic endocannabi-
noid modulation. 
Figure 2.  The sepsis cascade.
12 www.signavitae.com
and puncture (CLP) in mice. (36) They 
observed reduced survival time of CB2 
receptor knockout mice compared to 
wild type mice during systemic sepsis. 
Furthermore, the CB2 receptor knock-
out mice showed increased neutrophil 
recruitment and decreased neutrophil 
activation at the site of infection, lead-
ing to additional inflammatory damage. 
To observe CB2 receptor involvement 
in inflammatory mediation, they also 
used a highly specific CB2 receptor 
agonist called GP1a in wild type mice 
and observed increased mean survival 
time, decreased neutrophil recruitment, 
and increased neutrophil activation at 
the site of infection. Finally, the activity 
of a MAP kinase p38 known to regulate 
neutrophil function and priming was 
shown to be increased at the site of 
infection and associated with CB2 acti-
vation. (36) Altogether, these results 
indicated that activation of the CB2 
receptor during systemic inflammation 
can help reduce mortality and tissue 
damage. 
Another study by Csoka et al. also used 
a systemic inflammation model of sep-
sis through cecal ligation and puncture. 
(37) However, in the findings of this 
study they showed that CB2 receptor 
knockout mice have significantly lower 
mortality rates as well as decreased 
number of bacteria within the blood, but 
similar levels of bacteria in the periton-
eal lavage fluid when compared to wild 
type mice. They also measured serum 
levels of IL-10, an anti-inflammatory 
cytokine produce by macrophages, 
because an overproduction of this cyto-
kine can impair immune defense to 
bacterial pathogens. They observed 
lower levels of IL-10 in both the blood 
serum and peritoneal lavage of knock-
out mice compared to wild type. All of 
these results indicated that CB2 recep-
tor activation during systemic sepsis 
increased IL-10 overproduction caus-
ing an increase in bacterial invasion 
into the blood, ultimately resulting in 
increased mortality rates. (37) 
Multiple factors may help explain the 
inconsistency reported in studies of 
manipulating the CB2 receptor dur-
ing a septic state. (36,37) A possible 
explanation could be the severity of 
sepsis, where certain factors may play 
a crucial role in determining the role of 
the endocannabinoid receptors. Stud-
ies from our own lab indicate that in 
a more chronic stage of sepsis, inhib-
ition of CB2 receptors reduced leuko-
cyte activation and restored capillary 
perfusion. (34) Furthermore the stage 
of sepsis immunopathogenesis could 
be different between the mice used in 
these two studies. (36,37) For example, 
activation of the CB2 receptors dur-
ing the immunosuppressed stage of 
sepsis can cause increased mortality, 
possibly explaining the results seen by 
Csoka and colleagues. Taken together, 
all these results indicate that early in 
disease progression of sepsis, activa-
tion of the CB2 receptors may be bene-
ficial given that it increases activation of 
neutrophils at the site of infection, while 
preventing additional neutrophil recruit-
ment. However, in the latter stages 
of sepsis, an inhibition of CB2 recep-
tors may be beneficial in order to pre-
vent additional inflammatory damage 
incurred by preventing the activation of 
more leukocytes. Additional research 
needs to be conducted in order to 
strengthen these conclusions. 
Degradative Enzymes
Apart from manipulating the receptors 
themselves, regulation of endocanna-
binoid levels by targeting their enzym-
atic degradation may provide poten-
tial therapeutic benefit during sepsis. 
Although significant work has been 
carried out to-date on some of these 
endocannabinoid degradative enzymes, 
(10,27,38,39) since their discovery, to 
our knowledge, only a few studies have 
investigated the role of specific enzymes 
in sepsis. (40,41) With respect to FAAH, 
the key hydrolase for AEA degradation, 
cytokines such as IL-4 & IL-10 have 
been shown to influence FAAH activity 
Figure 3. Production and degradation of endocannabinoids AEA & 2-AG. Phos-
pholipid precursors are modified by N-acylphosphatidylethanolami-
ne phospholipase D (NAPE-PLD) and Diacylglycerol lipase (DAGL) 
to produce AEA and 2-AG respectively. MAGL degrades 2-AG into 
arachidonic acid and glycerol, while FAAH degrades AEA into ara-
chidonic acid and ethanolamine.  
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by increasing its activity, (40) and sep-
tic patients show a down-regulation of 
FAAH expression, leading to increased 
available AEA levels. (40,41) This is con-
sistent with the elevation in AEA levels 
seen in experimental models in which 
FAAH activity is lost. (42) Increased AEA 
levels may be beneficial during the initial 
stages of sepsis to stimulate CB2 recep-
tors and help combat the exaggerated 
immune response. However, sustained 
elevated AEA levels can also be detri-
mental in the latter stages of sepsis by 
further suppressing the immune system, 
causing a heightened vulnerability to the 
invading pathogens. To our knowledge, 
the role of MAGL inhibition on sepsis 
and inflammation has not yet been 
documented, but chronic loss of MAGL 
function is associated with increased 
2-AG levels, CB1 desensitization and 
hyperalgesia. (43)  
Our lab has explored the therapeutic 
potential of FAAH inhibition in experi-
mental sepsis (endotoxemia). Rats were 
treated with a selective FAAH inhibitor, 
URB597, at different dosages, prior to 
the induction of sepsis. Furthermore, a 
separate group of rats were also treated 
with a selective CB2 antagonist along 
with URB597 and LPS, to verify the role 
of CB2 receptor activation. Our results 
showed that an LPS challenge signifi-
cantly increased leukocyte adhesion to 
the endothelial lining in the collecting 
and post-capillary venules of the intes-
tinal submucosa. Furthermore, capillary 
perfusion, measured through functional 
capillary density (FCD), was significantly 
decreased in both the circular and longi-
tudinal muscle layer of the gut, as well 
as the intestinal mucosal villi during the 
LPS challenge. The group pretreated 
with URB597 showed a prevention of the 
increased leukocyte adhesion promoted 
by LPS. URB597 pre-treatment also pre-
vented the LPS induced reduction in 
FCD, however the effect was only seen 
at the higher dose of URB597 and only 
in the circular muscle layer of the gut. 
The use of the CB2 receptor antagonist, 
AM630, along with LPS and URB597 
reversed the actions of the FAAH inhib-
itor on leukocyte adhesion for both col-
lecting and post-capillary venules. This 
result indicates that the protective effects 
of URB597 were mediated by CB2 acti-
vation. However, AM630 administration 
did not have any significant impact on 
the effects of URB597 on the FCD either 
in the mucosa or intestinal muscle lay-
ers. (44) 
Conclusion
The endocannabinoid system modu-
lates the immune response in experi-
mental sepsis. Manipulat ing the 
endocannabinoid system may have 
potential therapeutic benefit in clin-
ical sepsis where immune and inflam-
matory dysfunction can be detri-
mental. Multiple targets exist within 
the endocannabinoid system, e.g. the 
system can be targeted at the level of 
receptors by administration of synthet-
ic compounds, similar to the endocan-
nabinoids, which either increase or 
inhibit receptor activation to provide 
the desired therapeutic effect. Alterna-
tively, the endogenous enzymes that 
degrade endocannabinoids or canna-
binoid-like lipids can also be targeted 
in order to manipulate the levels of 
endocannabinoids. Proper identifica-
tion of the septic stage is crucial to 
determine the adequate therapeutic 
response that will be most beneficial. 
Due to the biphasic nature of sepsis 
immunopathology, immune suppres-
sion through endocannabinoid modu-
lation can help mitigate the hyper-
immune response during the early 
septic state, while immune activation 
may be beneficial in later stages. 
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